期刊
VIRUSES-BASEL
卷 13, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/v13071237
关键词
SARS-CoV-2; COVID-19; vaccine
类别
资金
- FAPESP-COVID Program [2020/04836-0]
- Centers for Research in Emerging Infectious Diseases (CREID) by the National Institutes of Health (NIH) [1U01AI151807]
- FAPESP [2013/21719/3]
The development of effective vaccines against COVID-19 has helped in reducing the transmission of the virus, but the emergence of variants poses challenges. Breakthrough infections after vaccination highlight the importance of continued vigilance and efforts to prevent and diagnose infections among vaccinated individuals.
The rapid development of efficacious and safe vaccines against coronavirus disease 2019 (COVID-19) has been instrumental in mitigating the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Moreover, the emergence of SARS-CoV-2 variants raised concerns on the efficacy of these vaccines. Herein, we report two cases of breakthrough infections with the P1 variant in patients vaccinated with CoronaVac, which is one of the two vaccines authorized for emergency use in the Brazilian immunization program. Our observations suggest that the vaccine reduced the severity of the disease and highlight the potential risk of illness following vaccination and subsequent infection with the P1 variant as well as for continued efforts to prevent and diagnose infection in vaccinated persons.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据